Primary Hepatocytes Market Size Worth US$ 486 Million with 6.6% CAGR by 2034: Fact.MR Report

The global primary hepatocytes market was valued at approximately US$ 189.5 million in 2019. Driven by continuous advancements in liver cell research across both public institutions and private biotech companies, the demand for high-quality primary hepatocytes is steadily increasing. Reflecting these trends, Fact.MR projects the market to reach an estimated value of around US$ 255.6 million by 2024.

With liver toxicity studies exploring new applications and therapeutic approaches, the demand for reliable sources of fresh hepatocytes to support in vitro liver models is expected to grow significantly in the near future.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9643

What Emerging Trends Are Driving Growth in the Primary Hepatocytes Market?

"Surge in In Vitro Liver Toxicology Testing and Growing Regulatory Focus on Drug Safety"

As the healthcare landscape increasingly shifts toward personalized medicine, there is a growing demand for hepatocytes that accurately reflect individual genetic variations. In response, key industry players are expanding their offerings of primary hepatocytes sourced from diverse genetic backgrounds to support customized drug response analysis and liver toxicity research.

Advancements in hepatocyte preservation techniques have also significantly improved the viability and functionality of cryopreserved cells. As a result, suppliers are intensifying their efforts to refine cryopreservation technologies, aiming to deliver high-quality, ready-to-use hepatocytes that meet evolving research and clinical requirements.

Country-wise Insights

In East Asia, industry participants are catering to the region's robust pharmaceutical sector by supplying hepatic cells essential for understanding liver disease progression and formulating effective treatments. The region's dynamic healthcare infrastructure and research investments are further fueling demand for primary hepatocytes.

In North America, the primary hepatocytes market is projected to reach a valuation of approximately US$ 88 million by 2024. A key growth driver in this region is the expanding network of biobanking programs, which ensures a steady supply of diverse hepatocyte samples for a wide range of research and drug development applications.

According to Fact.MR, the market for primary hepatocytes is expected to grow at a CAGR of 5.4%, reaching a total value of about US$ 150 million by the end of 2034.

Category-wise Insights

Biopharmaceutical companies account for over half of the total demand for primary hepatocytes. These cells are critical for early-stage drug testing, making them indispensable in drug discovery pipelines. The segment is forecast to grow at a CAGR of 6.1%, with projected revenues reaching US$ 235.8 million by 2034.

Academic and research institutions are also showing increased interest in primary hepatocytes, driven by their applications in collaborative research efforts. Partnerships between hepatocyte suppliers and academic organizations are expanding the scope of innovation in liver cell research.

Competitive Landscape

Leading players in the global primary hepatocytes market include Thermo Fisher Scientific, Corning Inc., Lonza, Axol Bioscience Ltd., LifeNet Health, SEKISUI XenoTech, LLC, Cytes Biotechnologies, Cell Biologics, Inc., ZenBio, Inc., BioIVT, ScienCell Research Laboratories, Inc., Kerafast, Takara Bio Inc., and Kosheeka.

Established vendors have cultivated long-term collaborations with researchers focused on bioengineered liver regeneration and therapeutic innovations. Meanwhile, new entrants are gaining traction by exploring novel bioengineering applications for liver cell assays.

Recent Developments

In May 2022, BioIVT, a U.S.-based company, introduced a new line of human primary hepatic cells, including high-purity Kupffer cells. These additions aim to support the development of therapies for various liver diseases.
In January 2022, Charles River Laboratories acquired HemaCare Corp., a major supplier of primary hepatocytes for both research and clinical use. This acquisition is part of Charles River's strategy to expand its capabilities in the fast-growing cell therapy market.

Browse Full Report: https://www.factmr.com/report/primary-hepatocytes-market

Key Segments Covered by Primary Hepatocytes Industry Survey Report

By Product Type:
Cryopreserved Suspension Hepatocytes
Fresh Suspension Hepatocytes
3D (Spheroid) Hepatocytes
Expanded Hepatocytes (Plateable)
Non-characterized Hepatocytes
By Species Type:
Humans
Rats
Mice
Dogs
Monkeys
Horses
Other Species
By Application or Assay:
Cell Viability Assays
Cytochrome Enzyme Activity
High Content Cytotoxicity
Transporter Inhibition Assays
In Vitro Intrinsic Clearance
Phospholipoid Assays
Other Applications or Assays
By End User Verticals:
Biopharmaceutical Companies
Academic and Research Institutes
Contract Research Organizations
Other End User Verticals
By Region:
North America
Europe
Latin America
East Asia
South Asia & Oceania
The Middle East & Africa (MEA)

Check out More Related Studies Published by Fact.MR:

Paper Diagnostics Market
https://www.factmr.com/report/5454/paper-diagnostics-market
Geriatric Medicines Market
https://www.factmr.com/report/4746/geriatric-medicines-market
Glaucoma Therapeutics Market
https://www.factmr.com/report/4775/glaucoma-therapeutics-market
Monopolar Electrosurgery Market
https://www.factmr.com/report/4845/monopolar-electrosurgery-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.